As the Federal Government moves closer to reclassifying Hydrocodone combination product, (Lorcet, Lortab, Vicodin, Vicoprofen, Tussionex, Norco ), from a schedule III controlled substance, to a schedule II controlled substance, efforts are being made to maintain prescription rights through SB1043.
SUMMARY: The Drug Enforcement Administration (DEA) proposes to reschedule hydrocodone combination products from schedule III to schedule II of the Controlled Substances Act. This proposed action is based on a rescheduling recommendation from the Assistant Secretary for Health of the Department of Health and Human Services and an evaluation of all other relevant data by the DEA. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule II controlled substances on persons who handle (manufacture, distribute, dispense, import, export, engage in research, conduct instructional activities, or possess) or propose to handle hydrocodone combination products.
SB 1043 Allows naturopathic physicians to prescribe substances that are reclassified from Schedule III to Schedule II after January 1, 2014. SB 1043 was signed by Governor Brewer on 4/22/2014
Proper Prescribing is your responsibility as a physician.
The Controlled Substances Prescription Monitoring Program (CSPMP) is a program developed to promote the public health and welfare by detecting diversion, abuse, and misuse of prescription medications classified as controlled substances under the Arizona Uniform Controlled Substances Act. A.R.S. § 36-2606 requires each medical practitioner who is licensed under Title 32 and who possesses a DEA license to register with the CSPMP. The CSPMP functions as a central repository of all prescriptions dispensed for Schedule II,III and IV controlled substances in Arizona. As a physician, you may request information from the repository to assist in treating patients, and identifying and deterring drug diversion.
Knowing the signs of drug seeking behavior is a start.
While directed at Arizona pharmacists, the information is beneficial to physicians who prescribe controlled substances.
You are encouraged to take advantage of the CSPMP to review patient profiles prior to prescribing any controlled substance, or during the course of treatment, should warning signs be observed.
Gail Anthony, Executive Director